Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nesta is an oral fixed-dose combination tablet containing drotaverine hydrochloride and mefenamic acid, developed and marketed by Thrift Pharmaceuticals. It is indicated for the symptomatic relief of pain associated with smooth muscle spasms and inflammation, including menstrual pain (dysmenorrhea), abdominal cramps, irritable bowel syndrome (IBS), and biliary or renal colic. Drotaverine is an antispasmodic agent that selectively inhibits phosphodiesterase 4 (PDE4), leading to increased intracellular cyclic adenosine monophosphate (cAMP) levels and subsequent relaxation of smooth muscle. Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, thereby blocking prostaglandin synthesis to provide analgesic and anti-inflammatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on drotaverine + mefenamic acid.